Good - I have rich content from Katzung's. Now I have enough to compose a thorough, well-structured answer. Let me compile it.
Nitrates
Nitrates are organic nitric acid esters of polyalcohols. They are among the oldest cardiovascular drugs still in regular clinical use - nitroglycerin has been used for over 160 years.
Prototype and Members
| Drug | Route / Formulation |
|---|
| Nitroglycerin (glyceryl trinitrate) | Sublingual tablet, spray, IV, transdermal patch, buccal |
| Isosorbide dinitrate | Sublingual, oral |
| Isosorbide mononitrate | Oral (active metabolite, avoids first-pass) |
| Pentaerythritol tetranitrate (PETN) | Oral |
| Amyl nitrite | Inhalation (obsolete for angina) |
Mechanism of Action
Nitrates must be bioactivated enzymatically to release nitric oxide (NO). Key enzymes include:
- Aldehyde dehydrogenase isoform 2 (ALDH2) - primary enzyme for nitroglycerin and PETN
- Glutathione S-transferase - also contributes in smooth muscle
The NO is released as free nitrite, then converted to NO, which (complexed with cysteine) binds the heme group of soluble guanylyl cyclase, raising intracellular cGMP. Elevated cGMP activates protein kinase G (PKG), leading to:
- Dephosphorylation of myosin light chains
- Smooth muscle relaxation
- Vasodilation - predominantly venous at low doses, arterial at higher doses
Production of PGI2/PGE and membrane hyperpolarization may also contribute. There is no direct autonomic receptor involvement, though autonomic reflexes are commonly triggered by the resulting hypotension.
- Katzung's Basic and Clinical Pharmacology, 16th Edition
- Braunwald's Heart Disease
Pharmacokinetics
Key point: high first-pass hepatic metabolism. The liver contains a high-capacity organic nitrate reductase. Oral bioavailability of nitroglycerin and isosorbide dinitrate is typically <10-20%.
| Feature | Detail |
|---|
| Preferred route (acute) | Sublingual - bypasses first-pass, onset 1-3 min |
| Plasma half-life (unchanged drug) | 2-8 minutes |
| Metabolite half-life | Up to 3 hours (active) |
| Excretion | Renal (glucuronide conjugates of denitrated metabolites) |
| Isosorbide mononitrate | Already the active metabolite - no first-pass problem, good oral bioavailability |
| Transdermal | Sustained 24-hour delivery; tolerance problem if used continuously |
Sublingual tablets can lose potency from volatilization; they should be stored in tightly closed glass containers (not plastic).
- Katzung's Basic and Clinical Pharmacology, 16th Edition
Cardiovascular Effects
Nitrates relax ALL smooth muscle regardless of the cause of preexisting tone. They have essentially no direct effect on cardiac or skeletal muscle.
Venous (dominant at therapeutic doses)
- Venodilation → reduced venous return → decreased LV preload
- Reduced LV end-diastolic volume and pressure → decreased myocardial wall tension and O2 demand
Arterial (at higher doses)
- Dilation of epicardial coronary arteries (important in vasospastic angina)
- Increased collateral blood flow to ischemic myocardium
- Systemic arteriolar dilation → reduced afterload
Hemodynamic result in angina
-
Reduced myocardial O2 demand (via preload and afterload reduction)
-
Improved O2 supply (coronary vasodilation + collaterals)
-
Harrison's Principles of Internal Medicine 22E (2025)
Clinical Indications
- Stable angina - sublingual NTG for acute relief; long-acting nitrates for prophylaxis
- Unstable angina / NSTEMI - IV nitroglycerin
- Vasospastic (Prinzmetal) angina - particularly useful (coronary vasodilation)
- Acute decompensated heart failure - reduce preload and afterload
- Hypertensive emergencies - IV nitroglycerin or nitroprusside
- Acute MI - cautious use to reduce ischemia (avoid if hypotension or RV infarct)
- Esophageal spasm - smooth muscle relaxation
Nitrate Tolerance
A major limitation of long-acting nitrate therapy.
Mechanism (multifactorial):
- Depletion of tissue sulfhydryl (SH) groups (e.g., on cysteine), reducing capacity to generate NO
- Increased generation of reactive oxygen species (free radicals) during nitrate metabolism
- Diminished availability of calcitonin gene-related peptide (CGRP), a potent endogenous vasodilator
- Neurohormonal counterregulation (RAAS activation, sympathetic stimulation)
Prevention: A nitrate-free interval of 8-12 hours each day (typically overnight for patches) prevents tolerance. Sulfhydryl donors (e.g., N-acetylcysteine) can partially restore responsiveness.
- Katzung's Basic and Clinical Pharmacology, 16th Edition
Adverse Effects
| Effect | Mechanism / Notes |
|---|
| Headache | Meningeal vasodilation - most common side effect; often diminishes with continued use |
| Hypotension / dizziness | Venodilation + reflex tachycardia |
| Reflex tachycardia | Baroreceptor response to BP drop |
| Flushing | Cutaneous vasodilation |
| Methemoglobinemia | Rare; more of a risk with amyl/isobutyl nitrites |
| Syncope | Particularly on standing (orthostatic) |
Contraindications
- Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) - absolute contraindication - combined use causes severe, potentially fatal hypotension (both increase cGMP)
- Right ventricular infarction - preload-dependent, nitrates worsen hypotension
- Severe aortic stenosis - fixed outflow obstruction; hypotension is dangerous
- Hypotension (SBP <90 mmHg)
- Hypertrophic obstructive cardiomyopathy - can worsen outflow obstruction
Drug Interactions
- PDE5 inhibitors - see above (most critical)
- Beta-blockers and calcium channel blockers - used together with nitrates to prevent reflex tachycardia and provide additive antianginal benefit
- Antihypertensives / alcohol - additive hypotension
Summary Table
| Property | Detail |
|---|
| Class | Organic nitrates (vasodilators) |
| MOA | NO → cGMP↑ → smooth muscle relaxation |
| Primary site | Veins >> arteries at low doses |
| Main benefit in angina | Preload reduction + coronary vasodilation |
| Prototype | Nitroglycerin |
| Key limitation | Tolerance (nitrate-free interval required) |
| Fatal interaction | PDE5 inhibitors |
Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed. | Harrison's Principles of Internal Medicine, 22E | Lippincott Illustrated Reviews: Pharmacology | Braunwald's Heart Disease